A case of scaly annular plaques

- Patient Presentation
- History
- Differential Diagnosis
- Examination
- Investigations
- Discussion
- Treatment
- Final Outcome
- References
- Evaluation - Questions & answers
- MCQ

Patient Presentation

A 45 year old male is referred from outpatient clinic to a hospital dermatology department with well demarcated erythematous scaly annular plaques, scattered on his trunk, face and scalp, which is not responding to conventional psoriasis treatment.

Acknowledgements:

1. Dr Carol Hlela, Institute of Infectious Disease and Molecular Medicine, University of Cape Town

2. The case was supplied by the Department of Dermatology, Groote Schuur Hospital

Partnership

We have partnered with The International Union of Basic and Clinical Pharmacology (IUPHAR) to bring you in-depth information about drugs and pharmacology with links to the Guide to ImmunoPharmacology.

History

History revealed that the patient had suffered from psoriasis for the past 6 years. During this time he was under the care of a general practitioner who treated his psoriasis with oral and topical steroids—without any improvement. Following these 6 years of treatment without relief the patient was referred to specialist care. At the Dermatology outpatient department of a tertiary hospital the patient was started on different topical therapies which included Dovonex ointment, a synthetic Vitamin D3.
derivative, and UV phototherapy. However, despite months of follow ups and treatment adjustments he still remained poorly controlled. Now at his 12 month visit he has been admitted to hospital due to a severe flare up of psoriasis. He has been initiated on topical Anthralin (dithranol) in addition to his current treatment while continuing UV phototherapy.

**Past Medical History**

No history of joint pain or stiffness.

**Past Surgical History**

Nil

**Family History**

Father- hypertension on treatment  
Mother- well  
No family history of psoriasis or arthritis

**Allergies**

None known

**Medication**

Dithranol (Anthralin), *Salicylic acid*, Dovonex and UV phototherapy

**Social History**

Non smoker  
No alcohol or illicit drug use

**Differential Diagnosis**

Psoriasis  
Nummular dermatitis  
Lichen planus  
Mycoses Fungoides (MF)

**Examination**
ON ADMISSION:

Appearance:

Ambulatory male, awake, alert and co-operative

Vitals

Temperature: afebrile
Blood pressure: 132/76
Heart rate: 75  
Respiratory rate: 16  

General  
Scattered erythematous medium to large plaques on chest, upper back, lower limbs, thighs, scalp and face, with silvery scale.  
No palpable lymph nodes, jaundice, pallor or oedema  

Chest  
Chest clear  

Cardiovascular  
Normotensive  
No murmurs, no added heart sounds  

Abdomen  
No distension or tenderness. Bowel sounds present.  

Neurological  
Normal level of consciousness, alert and co-operative  
Gait, power, tone, sensation and reflexes intact and functioning within normal limits.  

Musculoskeletal  
No swellings, no effusions, no tenderness  
No joint deformities  
Normal range of motion in all joints  

Dermatological  
Scattered erythematous medium-large plaques on chest, upper back, lower limbs, thighs, scalp and face, with silvery scaling. (See figure 1)  
Flexural involvement.  
Positive Auspitz sign (capillary bleeding occurring after overlying scale removed) 
PASI score (psoriasis area severity index) was E$_3$S$_3$I$_3$, indicating that erythema, scale and induration were all severe, with BSA (body surface area of >25%). The PASI is a measure of overall psoriasis severity and coverage that assesses body surface area, erythema and scaling.
Scalp lesions extended to the face.
Several lesions on the upper back were tumour-like

**Investigations**

**On Admission:** blood results were unremarkable

<table>
<thead>
<tr>
<th>Admission</th>
<th>Patient result</th>
<th>Reference ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBCC</td>
<td>9.09</td>
<td>4-12x10^9/L</td>
</tr>
<tr>
<td>FBC</td>
<td>14.8</td>
<td>12.1-15.2g/L</td>
</tr>
<tr>
<td>Platelets</td>
<td>265</td>
<td>140-450x10^9/L</td>
</tr>
<tr>
<td>Diff Count:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrophils</td>
<td>6.43</td>
<td>2.0 - 7.50x10^9/L</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>1.57</td>
<td>1.0 - 4x10^9/L</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>0.2800000000000003</td>
<td>0.0 .0.45 x10^9/L</td>
</tr>
<tr>
<td>Urea</td>
<td>4.0999999999999996</td>
<td>(2.5-6.4 mmol/L)</td>
</tr>
<tr>
<td>Creatinine</td>
<td>81</td>
<td>(62-115 mmol/L)</td>
</tr>
<tr>
<td>Liver function tests</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total bilirubin</td>
<td>10</td>
<td>0-21µmol/l</td>
</tr>
<tr>
<td>Conjugated bilirubin</td>
<td>2</td>
<td>0-6µmol/l</td>
</tr>
<tr>
<td>Total Protein</td>
<td>73</td>
<td>60-85g/l</td>
</tr>
<tr>
<td>Albumin</td>
<td>45</td>
<td>35-52g/l</td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>77</td>
<td>40-120 U/l</td>
</tr>
<tr>
<td>y-Glutamyl transferase</td>
<td>16</td>
<td>0-35 U/l</td>
</tr>
<tr>
<td>Alanine transaminase</td>
<td>16</td>
<td>5-40 U/l</td>
</tr>
<tr>
<td>Lactate dehydrogenase</td>
<td>450</td>
<td>240-480 U/l</td>
</tr>
<tr>
<td>Amylase</td>
<td>46</td>
<td>28-110 U/l</td>
</tr>
<tr>
<td>Admission</td>
<td>Patient result</td>
<td>Reference ranges</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Lipase</td>
<td>42</td>
<td>0-60 U/l</td>
</tr>
</tbody>
</table>

**Skin Biopsy:**

Due to the unusual morphology of some of his lesions on the upper back, being tumour like, a skin biopsy was performed to exclude Mycoses Fungoides (MF), but the skin biopsy confirmed Psoriasis.

**Full Report:**

Skin sections show a heavy neutrophilic crust with both hyperkeratosis and parakeratosis overlying a spongiotic and acanthotic epidermis. There is chronic inflammatory infiltrate of lymphocytes and scattered neutrophils in the superficial dermis, but no lichenoid infiltrate noted. These histologic features are in keeping with Psoriasis.

**Discussion**

**Introduction**

Our presenting case is that of a 45 year old man with well demarcated erythematous, scaly, annular plaques, scattered on his trunk, face and scalp, consistent with psoriasis. For several years his disease was poorly managed. More recently he has received appropriate therapy with topicals and phototherapy but has remained refractory to treatment, necessitating the need for systemic medication.

To begin our discussions on the development of psoriasis we will start with an overview. Psoriasis is a complex, chronic, multifactorial, inflammatory disease that involves hyperproliferation of the keratinocytes in the epidermis. The disease manifestation is thought to be the result of an interplay between a genetic predisposition and a range of environmental factors (triggers) including injury, infection, allergy, extremes of temperature, alcohol use, chemicals or stress, resulting in an inflammatory response. Furthermore different clinical patterns of psoriasis are described, each thought to have a specific etiological mechanism:

Psoriasis vulgaris, is the most common and is seen in approximately 90% of patients. Presenting typically with red, scaly, symmetrically distributed plaques on extensor surfaces- as is seen in a severe form in our case study patient.

Guttate psoriasis, is characterized by the eruption of small papules on the upper trunk and proximal extremities, often but not exclusively triggered by Group A streptococcal throat infections.

Inverse psoriasis, is characterised by lesions in a flexural distribution with involvement of
axillae, groin and perineum.
Erythrodermic psoriasis represents a generalized form of disease that affects more than 90% of body surface area.
Pustular psoriasis, is characterised by predominantly pustular lesions.

For the ease of demonstrating the development of psoriasis our discussion and graphics have remained general with Psoriasis vulgaris as our chosen clinical pattern and *infection* as the inflammatory trigger. However we will indicate when a specific etiological factor has been identified.

![Overview: development of psoriasis](image)

Following exposure to a triggering event skin-resident dendritic cells, known as Langerhans’ cells become activated and produce proinflammatory cytokines IL-1, and TNF-a.

![Inflammatory trigger ag skin infection](image)

The activated Langerhans’ cells then migrate to skin lymph nodes and present antigens to CD4+ T cells. The phenotype of activated CD4+ T cells is dependent on the type of cytokines produced by the antigen presenting cells. Although Th1 and Th22 CD4+ T cells also participate in the inflammatory response, Th17 cells have been shown to play a central role in the development of psoriasis due to the secretion of IL-17A and IL-17F. The differentiation of naïve CD4+ T cells into Th17 CD4+ T cells
results from cytokine stimulation by TGF-β and IL-6. Additional enhancement of Th17 CD4+ T cell development occurs by additional stimulation by IL-23. Activated Th17 CD4+ T cells clonally expand and migrate out of the lymphoid tissues and extravasate into the dermis where IL-17A and IL-17F is produced. IL-17A and IL-17F activates keratinocytes which in turn secrete cytokines, attracting and recruiting more immune cells and in so doing setting up a self-perpetuating inflammatory process in the skin. These mechanisms of differentiation, extravasation, activation, secretion and recruitment will be discussed here in further detail.

**Differentiation of Th17 CD4+ helper T cells**

Following activation of Langerhans’ cells in the T cell zones of the skin lymph nodes, the group of cytokines secreted by the Langerhans’ cell will determine the phenotype of the activated T cell. In this case, TGF-beta, IL-6 and IL-23 will cause naïve CD4+ T cells to differentiate into Th17 CD4+ helper T cells. These activated T cells then undergo clonal expansion with the resulting effector cells migrating out of the lymph node to the dermis of the skin.

**Extravasation of effector Th17 CD4+ T cells into skin**
Homing of Th17 effector CD4+ helper T cells to the skin and extravasation is a multi-step process that begins with initial binding of CLA and CCR4 receptors expressed on T cells to E-selectin and CCL17 chemokine ligands on skin post-capillary venule endothelial cells, respectively. Additional stabilisation then occurs by binding of T cell integrins LFA-1 and VLA-4 to endothelial cell adhesion molecules ICAM-1 and VCAM-1, respectively. The T cell then extravasates into the dermis by diapedesis. Completing the migration of Th17 effector cells from skin lymph nodes to the dermis, where activation of keratinocytes will now take place.

**Activation of keratinocytes by IL-17**

The Th17 CD4+ helper T cells, which have migrated into the dermis, are so called because they secrete the pro-inflammatory cytokine IL-17. Pro-inflammatory cytokines stimulate other cells to respond to an infection. There are variant isoforms of IL-17, currently six have been identified and designated IL-17A through to F. Th17 polarised T cells have been found to secrete the isoforms IL-17A and IL-17F and bind the heterodimeric IL-17 receptor composed of IL-17RA and IL-17RC chains. This IL-17 receptor has been found to be expressed on epithelial cells such as keratinocytes, that become activated upon stimulation of the IL-17 receptor.
Secretions from activated keratinocytes

Once keratinocytes are activated by IL-17 they go on to produce and secrete various antimicrobial peptides and immunomodulatory cytokines. Antimicrobial peptides such as beta-defensins and cathelicidins have been identified as playing a role in the control of micro-organisms. In particular cathelicidin LL-37 is speculated to have a disease modifying function in psoriasis. The various immunomodulatory cytokines produced and secreted by keratinocytes and their role in the disease process will be discussed here in further detail.

Secretion of IL-17C and IL-36 by keratinocytes

Keratinocytes produce the IL-17C isoform of IL-17 that binds the alternative IL-17 receptor composed of the IL-17RA and IL-17RE chain. IL-17C does not bind to the same receptor as IL-17A and IL-17F. The IL-17C receptor is also expressed by keratinocytes, and binding activates the cell. Similarly, keratinocytes produce IL-36 that also activates keratinocytes by binding to the IL-36 receptor. IL-36Ra is an IL-36 receptor antagonist molecule that competes with IL-36 for binding to the IL-36 receptor (and modulates/reduces excessive keratinocyte responses to IL-36). Genetic mutations in the IL-36Ra gene that encode non-functional IL-36a proteins have been shown to cause pustular psoriasis due to increased stimulation of the IL-36 receptors.
Activated keratinocytes produce CCL20, a chemokine that binds to the CCR6 chemokine receptor expressed by immune cells such as myeloid dendritic cells, Th17 CD4+ helper T cells and gamma-delta CD4+ T cells. Recruitment of these CCR6+immune cells into the dermis is facilitated by CCL20 chemokine gradients.

Activated keratinocytes produce chemokines that recruit neutrophils to the dermis. CXCL1, -2 and -3 bind to the CXCR2 receptor expressed by neutrophils, while CXCL8 can bind to both CXCR1 and -2 receptors. In psoriasis, large numbers of neutrophils are recruited to inflamed skin due to these chemokines.

Clinically this inflammatory infiltrate of neutrophils seen in the superficial dermis, is a histologic feature in keeping with the diagnosis of psoriasis.
Secretion of VEGF by keratinocytes

Vascular endothelial cell growth factor (VEGF) is produced by activated keratinocytes and binds to the VEGFR2 receptor on skin capillary endothelial cells promoting angiogenesis. In psoriasis increased blood supply is evident below the epithelial cell layer of inflamed skin. The vessels are also dilated which gives psoriatic lesions a red colour.

Clinically this is in keeping with the positive Auspitz sign which is seen as capillary bleeding occurring after overlying scale removed typically seen in cases of psoriasis.

Cytokine secretion by recruited immune cells

An amplification of activation signals targeting keratinocytes occurs via cytokines produced by recruited immune cells. Th17CD4+ helper T cells, gamma-delta CD4+ T cells and neutrophils all produce IL-17A and IL-17F that can activate additional keratinocytes by binding to the IL-17R (RA and RC chain variant). Myeloid dendritic cells produce IL-1, IL-
Epidermal thickening, angiogenesis and plaque formation- characteristics of Psoriasis

The hallmark histological observation of psoriatic skin (see Figure 2 below) is a thickening of the epidermal cell layer, with defects in the normal development and maturation of keratinocytes and the formation of plaques. Accumulation of immune cells in the skin, particularly neutrophils occurs along with an increase in the number of immune cells.

Once this stage has been reached, irrespective of the trigger, the condition becomes self-perpetuating due to the constant cytokine stimulation (particularly IL-17) of keratinocytes and ongoing influx of inflammatory cells into the skin.

Please note: specific treatment options are available as targeted treatment of psoriasis. The mechanisms of how these various therapeutic agents act to reduce disease symptoms will be available in a future case study presentation.
Treatment

As patient was not tolerating appropriately administered conventional psoriasis treatment with topicals and phototherapy, he was switched to systemic treatment using Methotrexate (MTX) 25mg per week. He was also started on Folic Acid supplements.

Final outcome

Good response on commencement of MTX. He was last seen, 6 months after starting MTX and continues to be notably improving, with a PASI $E_2S_1I_1$, BSA5-10%.

References


Evaluation - Questions & answers

What was the final diagnosis?

Severe Psoriasis vulgaris, refractory to conventional treatment with topicals and phototherapy

Which innate immune cells become activated in the skin following some form of environmental exposure?

Langerhans cells

In the development of psoriasis Th1 and Th22 CD4+ T cells are known to play a role in the inflammatory response. However which cells are central to the development of psoriasis?

Th17 cells play a central role in the development of psoriasis due to the secretion of IL-17A and IL-17F. IL-17A and F are produced from activated Th17 CD4+ T that have migrated into the dermis. Here IL-17A and F activate keratinocytes to secrete cytokines, which results in a self-perpetuating inflammatory process as immune cells are attracted and recruited to the skin.
What determines the migration of Th17 CD4+ T cells to the dermis?

Homing of Th17 effector CD4+ helper T cells to the skin is determined by the CCL17 chemokine gradient. Once the cells have moved to the skin, these cells then bind to E-selectin and CCL17 chemokine ligands on skin post-capillary venule endothelial cells using CLA and CCR4 receptors expressed on T cells, respectively.

What antimicrobial peptides are produced by keratinocytes after IL-17 stimulation?

Antimicrobial peptides such as beta-defensins and cathelicidins have been identified as playing a role in the control of micro-organisms. In particular cathelicidin LL-37 is speculated to have a disease modifying function in psoriasis.

Which genetic mutation has been shown to cause a form of pustular psoriasis?

Genetic mutations in the IL-36Ra gene that encode non-functional IL-36a proteins leads to over-excessive IL-36 production and unregulated keratinocyte activation and ongoing inflammation.

There was a heavy neutrophil infiltration seen on the patient, what causes the recruitment of neutrophils to the inflammed skin?

Activated keratinocytes produce CXCL1, -2, and -3 which bind to CXCR2 on the surface of neutrophils.

Download images for this case

Multiple Choice Questions

Earn 1 HPCSA or 0.25 SACNASP CPD Points - Online Quiz

Download images for this case

Psoriasis 1.66 MB
Download

Immunopaedia.org.za